0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Contempo Updates | Clinician's Corner

New Avenues of Exploration for Erythropoietin

Kenneth Maiese, MD; Faqi Li, MD, PhD; Zhao Zhong Chong, MD, PhD
JAMA. 2005;293(1):90-95. doi:10.1001/jama.293.1.90.
Text Size: A A A
Published online

Discovery that the hormone erythropoietin (EPO) and its receptor play a significant biological role in tissues outside of the hematopoietic system has fueled significant interest in EPO as a novel cytoprotective agent in both neuronal and vascular systems. Erythropoietin is now considered to have applicability in a variety of disorders that include cerebral ischemia, myocardial infarction, and chronic congestive heart failure. Erythropoietin modulates a broad array of cellular processes that include progenitor stem cell development, cellular integrity, and angiogenesis. As a result, cellular protection by EPO is robust and EPO inhibits the apoptotic mechanisms of injury, including the preservation of cellular membrane asymmetry to prevent inflammation. As the investigation into clinical applications for EPO that maximize efficacy and minimize toxicity progresses, a deeper appreciation for the novel roles that EPO plays in the brain and heart and throughout the entire body should be acquired.

Figures in this Article

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Figure. Potential Mechanism of Erythropoietin Cytoprotection
Graphic Jump Location

Erythropoietin (EPO) and the EPO receptor (EPOR) prevent apoptosis and cellular inflammation through a series of pathways that originate with the binding of EPO to the EPOR to activate Janus-tyrosine kinase 2 (Jak2), phosphoinositide 3 kinase (PI 3-K), and protein kinase B (Akt). The signal transducer and activator or transcription (STAT) proteins are direct substrates of Jak2. Activation of the specific gene product STAT5 can regulate EPO mediated cell proliferation and protect against apoptosis. Downstream from activation of Jak2 and Akt, EPO modulates phosphorylation of the fork head family member FOXO3a, glycogen synthase kinase-3β (GSK-3β), and nuclear factor-κB (NF-κB). Hypoxia increases the expression of hypoxia-inducible factor-1 (HIF-1) resulting in the direct enhancement of EPO expression and a hypoxic-driven increase in EPOR expression. Erythropoietin maintains cellular integrity and prevents apoptosis through a number of pathways, such as those involving Bcl-xL (for the maintenance of mitochondrial membrane potential), the modulation of apoptosis protease activating factor (Apaf)-1, the release of cytochrome C, and the activation of caspases 1, 3, and 9. Erythropoietin also modulates cellular inflammation by inhibiting cellular phosphatidylserine membrane exposure and the subsequent targeting of cells for phagocytosis.

Tables

References

Letters

CME


You need to register in order to view this quiz.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 320

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();